• Leo F Buckley, Salvatore Carbone, Ahmed Aldemerdash, Nayyra Fatani, and John Fanikos.
• Department of Pharmacy Services, Brigham and Women's Hospital, Boston, Mass; Cardiovascular Division, Brigham and Women's Hospital, Boston, Mass. Electronic address: LFBuckley@bwh.harvard.edu.
• Am. J. Med. 2019 Jan 1; 132 (1): 16-24.

AbstractCardiovascular disease is responsible for 205 deaths per 100,000 persons annually and is the leading cause of death worldwide. The public health burden of cardiovascular disease is expected to continue to grow as the prevalence of many cardiovascular risk factors increases. Several novel classes of glucose-lowering, lipid-lowering, and weight-loss therapeutics have shown mortality benefits in outcomes trials. However, a large proportion of subjects in those trials had established cardiovascular disease, so, as a result, the role of these novel therapeutics in primary cardiovascular prevention is controversial. In this review, we highlight recent advances in the pharmacotherapeutic management of the cardiovascular risk factors of hyperglycemia, dyslipidemia, and obesity. We examine key subgroups within recent cardiovascular outcome trials, weigh the risks and benefits of several novel therapeutics, and provide practical insight into the use of these agents. Our article concludes with a look toward the future and provides the practitioner and scientist with an early view of emerging therapeutics that may play an important role in primary cardiovascular prevention.Copyright © 2019. Published by Elsevier Inc.

19 keywords...

hide…